News STADA Arzneimittel

Equities

SAZ

DE0007251803

Delayed Xetra Other stock markets			5-day change	1st Jan Change
- ^EUR	-.--%		-1.95%	-8.87%

2023	Alvotech, Stada Get EU Panel Backing for Stelara Biosimilar	MT
2021	Sanofi Divests 16 Brands From European Consumer Healthcare Portfolio	DJ

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Xbrane has received additional subscription undertakings corresponding to approximately SEK 18.1 million in the Company's rights issue	Mar. 04	AQ
Alvotech, Stada Get EU Panel Backing for Stelara Biosimilar	Nov. 10	MT
Calliditas announces filing with UK MHRA for Kinpeygo in IgA nephropathy	23-10-03	AQ
STADA and Calliditas announce the filing for full marketing authorization of Kinpeygo® in the EU	23-09-28	AQ
Calliditas Therapeutics announces full results from the NefIgArd Phase 3 trial published in The Lancet	23-08-15	AQ
STADA and Xbrane weigh options for ranibizumab biosimilar candidate	23-07-25	AQ
Xbrane announce U.S. FDA filing acceptance for a Lucentis® (ranibizumab) biosimilar candidate	23-06-21	AQ
STADA AND XBRANE LAUNCH XIMLUCI AS RANIBIZUMAB BIOSIMILAR IN GERMANY	23-05-26	AQ
STADA and Xbrane launch Ximluci® as ranibizumab biosimilar in Germany	23-05-26	AQ
STADA AND XBRANE SUPPLY XIMLUCI IN ENGLAND UNDER NHS CONTRACT	23-04-26	AQ
STADA and Xbrane supply Ximluci® (ranibizumab) in England under NHS contract	23-04-25	AQ
STADA and Xbrane launch ranibizumab to support patient access in Europe	23-04-03	AQ
European Biosimilar Regulatory Updates	23-02-08	AQ
Calliditas Receives Conditional Marketing Authorization from UK MHRA for Kinpeygo in IgA nephropathy	23-02-02	AQ
STADA and Xbrane obtain British approval for Ximluci® (ranibizumab) biosimilar referencing Lucentis®	23-01-17	AQ
STADA And Xbrane Announce Approval Of Ranibizumab Biosimilar In Europe	22-11-15	AQ
Calliditas Therapeutics - Interim Report Q3, 2022 Conditional Marketing Authorization in EU Granted for Kinpeygo	22-11-14	AQ
Interim Report Q3, 2022	22-11-14	AQ
STADA and Xbrane secure EU approval for Ximluci® (ranibizumab) biosimilar referencing Lucentis®	22-11-11	AQ
Calliditas partner STADA launches the first medicine authorized in the EU for treating primary IgA nephropathy	22-09-21	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News STADA Arzneimittel

Equities

SAZ

DE0007251803

Summary

Filters